Worth reading
45Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
43
¥ million (downward revision to full-year business revenue forecast)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Earnings presentationThird quarter of the fiscal year ending December 20265 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥55 million-16.0%
Operating profit¥-369 million
Ordinary income¥-364 million
Net income¥-513 million
Selling, general and administrative expenses¥232 million
Results for the three months of the current quarter
Business revenue
¥18 million
Operating Costs
¥141 million
Operating profit
¥-123 million
Non-Operating Income and Expenses
¥1 million
Ordinary income
¥-121 million
Net income for the current fiscal year
¥-127 million
Full-year earnings forecast
Business revenue
¥70 million
Operating Costs
¥586 million
Operating profit
¥-515 million
Non-Operating Income and Expenses
¥6 million
Ordinary income
¥-509 million
Net income for the current fiscal year
¥-700 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Expected to fall short of the initial assumptionsBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Loss of expected milestone income¥40 million
- Impairment Losses¥187 million
- Revision to full-year business revenue forecast¥-43 million
- Revision to full-year business expense forecast¥-95 million
- Revision to full-year operating profit forecast¥53 million
- Revision to full-year ordinary profit forecast¥54 million
- Revision to net profit for the period forecast¥-133 million
New initiatives
- Execution of a memorandum of understanding with Syntara
- Joint patent application with Mitsubishi Gas Chemical for an lncRNA H19-targeted nucleic acid drug
- Completion of Perfusio® trademark registration and preparation for regulatory approvals toward the start of manufacturing and marketing during fiscal 2027
- Completion of the relocation of the Shinkawasaki Research Institute
Key KPIsA metric the company considers important as a management benchmark.
- Webinar attendance (cumulative during the period)232 people
- Number of companies in contract negotiations8 companies
- New contract execution KPI2 Deals
- In-house pipeline generation KPI1 Projects
- Granted patents3 Deals
- Patents filed or under examination10 Deals
Risk amount incorporated into the outlookThe amount representing the range of variation the company expects in its forecast.
Amount
- ¥40 millionDetailsLoss of expected milestone income due to a change in the research plan caused by circumstances on the part of the joint research partner
- ¥187 millionDetailsImpairment loss on buildings and attached structures, and tools, furniture and fixtures
| Item | Details |
|---|---|
| Document type | Earnings presentation |
| Fiscal Period Covered | Third quarter of the fiscal year ending December 2026 |
| Net Sales | ¥55 million (YoY -16.0%) |
| Operating profit | ¥-369 million |
| Ordinary income | ¥-364 million |
| Net income | ¥-513 million |
| Selling, general and administrative expenses | ¥232 million |
| Results for the three months of the current quarter | Business revenue ¥18 million / Operating Costs ¥141 million / Operating profit ¥-123 million / Non-Operating Income and Expenses ¥1 million / Ordinary income ¥-121 million / Net income for the current fiscal year ¥-127 million |
| Full-year earnings forecast | Business revenue ¥70 million / Operating Costs ¥586 million / Operating profit ¥-515 million / Non-Operating Income and Expenses ¥6 million / Ordinary income ¥-509 million / Net income for the current fiscal year ¥-700 million |
| Self-assessment against the plan | Expected to fall short of the initial assumptions |
| Breakdown of Factors Affecting the Change | Factors Loss of expected milestone income / Amount ¥40 million, Factors Impairment Losses / Amount ¥187 million, Factors Revision to full-year business revenue forecast / Amount ¥-43 million, Factors Revision to full-year business expense forecast / Amount ¥-95 million, Factors Revision to full-year operating profit forecast / Amount ¥53 million, Factors Revision to full-year ordinary profit forecast / Amount ¥54 million, Factors Revision to net profit for the period forecast / Amount ¥-133 million |
| Key KPIs | Indicator name Webinar attendance (cumulative during the period) / Value 232 people / Year on year against the same period last year Not disclosed, Indicator name Number of companies in contract negotiations / Value 8 companies / Year on year against the same period last year Not disclosed, Indicator name New contract execution KPI / Value 2 Deals / Year on year against the same period last year Not disclosed, Indicator name In-house pipeline generation KPI / Value 1 Projects / Year on year against the same period last year Not disclosed, Indicator name Granted patents / Value 3 Deals / Year on year against the same period last year Not disclosed, Indicator name Patents filed or under examination / Value 10 Deals / Year on year against the same period last year Not disclosed |
| Risk amount incorporated into the outlook | Amount ¥40 million, ¥187 million |
| New initiatives | Execution of a memorandum of understanding with Syntara, Joint patent application with Mitsubishi Gas Chemical for an lncRNA H19-targeted nucleic acid drug, Completion of Perfusio® trademark registration and preparation for regulatory approvals toward the start of manufacturing and marketing during fiscal 2027, Completion of the relocation of the Shinkawasaki Research Institute |
Items this document does not state (17)
Gross Profit MarginOperating profit marginProgress against full-year forecastSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The research plan was changed due to circumstances on the part of the joint research partner, making it unlikely that the initially expected milestone income of ¥40 million will be recognized. In addition, an impairment loss of ¥187 million is expected to arise on buildings and attached structures, and tools, furniture and fixtures placed into use in fiscal 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.